What was the overall market valuation for the US head and-neck-cancer market in 2024?

The overall market valuation was $308.7 Million in 2024. Read More

What is the projected market valuation for the US head and-neck-cancer market by 2035?

The projected valuation for 2035 is $622.9 Million. Read More

What is the expected CAGR for the US head and-neck-cancer market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.59%. Read More

Which companies are considered key players in the US head and-neck-cancer market?

Key players include Merck & Co, Bristol-Myers Squibb, Roche, Amgen, Eli Lilly and Company, AstraZeneca, Novartis, Sanofi, and Pfizer. Read More

What are the main segments of the US head and-neck-cancer market?

The main segments include Type, Cancer Type, End User, and Diagnosis Method. Read More

What was the valuation for surgery in the US head and-neck-cancer market in 2024?

The valuation for surgery was between $80.0 Million and $160.0 Million in 2024. Read More

How much is the radiation therapy segment valued at in the US head and-neck-cancer market?

The radiation therapy segment was valued between $70.0 Million and $140.0 Million in 2024. Read More

What is the projected valuation for chemotherapy in the US head and-neck-cancer market by 2035?

The projected valuation for chemotherapy is expected to reach between $60.0 Million and $120.0 Million by 2035. Read More

What is the valuation range for oral cancer in the US head and-neck-cancer market?

The valuation range for oral cancer was between $80.0 Million and $160.0 Million in 2024. Read More

Which end user segment had the highest valuation in the US head and-neck-cancer market in 2024?

The hospitals segment had the highest valuation, ranging from $120.0 Million to $250.0 Million in 2024. Read More

US Head and Neck Cancer Market

US Head and Neck Cancer Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Cancer Type (Oral Cancer, Laryngeal Cancer, Nasopharyngeal Cancer, Throat Cancer, Salivary Gland Cancer), By End Users (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers) and By Diagnosis Method (Biopsy, Imaging Techniques, Endoscopy, Physical Examination) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.59%

2024 Market Size

$ 308.7 Million

2035 Market Size

$ 622.9 Million

Medical Device ● Updated April 2026 Report ID: MRFR/MED/16422-HCR | Pages: 100 | Author: Vikita Thakur, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Surgery
  2. 4.1.2 Radiation Therapy
  3. 4.1.3 Chemotherapy
  4. 4.1.4 Targeted Therapy
  5. 4.1.5 Immunotherapy
2. 4.2 Construction, BY Cancer Type (USD Million)
  1. 4.2.1 Oral Cancer
  2. 4.2.2 Laryngeal Cancer
  3. 4.2.3 Nasopharyngeal Cancer
  4. 4.2.4 Throat Cancer
  5. 4.2.5 Salivary Gland Cancer
3. 4.3 Construction, BY End User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Cancer Research Institutes
  3. 4.3.3 Ambulatory Surgical Centers
4. 4.4 Construction, BY Diagnosis Method (USD Million)
  1. 4.4.1 Biopsy
  2. 4.4.2 Imaging Techniques
  3. 4.4.3 Endoscopy
  4. 4.4.4 Physical Examination
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Merck & Co (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Amgen (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eli Lilly and Company (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Pfizer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY CANCER TYPE
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY DIAGNOSIS METHOD
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY CANCER TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY CANCER TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY END USER, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Head and Neck Cancer Market Segmentation

US Head and Neck Cancer Market By Type (USD Million, 2025-2035)

Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Immunotherapy

US Head and Neck Cancer Market By Cancer Type (USD Million, 2025-2035)

Oral Cancer
Laryngeal Cancer
Nasopharyngeal Cancer
Throat Cancer
Salivary Gland Cancer

US Head and Neck Cancer Market By End User (USD Million, 2025-2035)

Hospitals
Cancer Research Institutes
Ambulatory Surgical Centers

US Head and Neck Cancer Market By Diagnosis Method (USD Million, 2025-2035)

Biopsy
Imaging Techniques
Endoscopy
Physical Examination

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”